Morgan Stanley’s TrovaGene, Inc. Warrant TROVW Stock Holding History

Morgan Stanley’s Portfolio TROVW Stock Details TROVW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,400	Closed	-$1K	–	6769
2017 Q1	$1K	Hold	8,400	–	–	﹤0.01%	6542
2016 Q4	$3K	Sell	8,400 -2,322	-22%	-$1.91K	﹤0.01%	6363
2016 Q3	$14K	Buy	10,722 +7,434	+226%	+$15K	﹤0.01%	6036
2016 Q2	$8K	Hold	3,288	–	–	﹤0.01%	6127
2016 Q1	$13K	Sell	3,288 -1,452	-31%	-$4.7K	﹤0.01%	6065
2015 Q4	$14K	Sell	4,740 -1,100	-19%	-$3.79K	﹤0.01%	6161
2015 Q3	$23K	Hold	5,840	–	–	﹤0.01%	6015
2015 Q2	$44K	Buy	+5,840	New	+$37.3K	﹤0.01%	5904
2013 Q3	–	Sell	-15,000	Closed	-$62K	–	5448
2013 Q2	$62K	Buy	+15,000	New	+$47.1K	﹤0.01%	5169

Morgan Stanley's TROVW Position: Q2 2017 in Review

Morgan Stanley sold out of TrovaGene, Inc. Warrant (TROVW) in Q2 2017, closing a stake of 8,400 shares — an estimated $1K sold.

Morgan Stanley first reported a position in TROVW in Q2 2013 and held it in 9 quarters. The position peaked at $62K in Q2 2013. 0 funds tracked by Wall St. Rank hold TROVW as of Q2 2017.

Morgan Stanley reported no remaining TrovaGene, Inc. Warrant position as of Q2 2017 after selling out during the quarter.
Morgan Stanley sold 8,400 TrovaGene, Inc. Warrant shares in Q2 2017, an estimated $1K.
Morgan Stanley first reported a position in TrovaGene, Inc. Warrant in Q2 2013 and held it in 9 quarters.
Morgan Stanley's TrovaGene, Inc. Warrant position peaked at $62K in Q2 2013.
0 funds tracked by Wall St. Rank held TrovaGene, Inc. Warrant as of Q2 2017.

Based on Morgan Stanley's 13F filing for Q2 2017, filed 11 Aug 2017.